HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-François Jeannin Selected Research

Colonic Neoplasms (Colon Cancer)

6/2018Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.
4/2013Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
10/2006Nitric oxide-induced down-regulation of beta-catenin in colon cancer cells by a proteasome-independent specific pathway.
3/2004Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer.
8/2002Arginase activity is inhibited by L-NAME, both in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-François Jeannin Research Topics

Disease

18Neoplasms (Cancer)
06/2018 - 08/2002
6Breast Neoplasms (Breast Cancer)
05/2016 - 06/2004
5Colonic Neoplasms (Colon Cancer)
06/2018 - 08/2002
3Neoplasm Metastasis (Metastasis)
06/2007 - 09/2004
1Prostatic Neoplasms (Prostate Cancer)
01/2019
1Colorectal Neoplasms (Colorectal Cancer)
11/2014
1Peritoneal Neoplasms
04/2013
1Melanoma (Melanoma, Malignant)
09/2010
1Tachypnea
01/2010
1Septic Shock (Toxic Shock Syndrome)
01/2010
1Tachycardia (Tachyarrhythmias)
01/2010
1Leukopenia
01/2010
1Sepsis (Septicemia)
01/2010
1Leukocytosis (Pleocytosis)
01/2010
1Hypothermia
01/2010
1Pica (Geophagia)
06/2007
1Experimental Melanoma
06/2007
1Carcinoma (Carcinomatosis)
01/2005

Drug/Important Bio-Agent (IBA)

10Lipid AIBA
06/2018 - 03/2004
9Nitric Oxide (Nitrogen Monoxide)FDA Link
05/2016 - 09/2004
5Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
05/2016 - 09/2004
3Toll-Like Receptors (Toll-Like Receptor)IBA
05/2016 - 06/2007
3CytokinesIBA
11/2015 - 01/2005
3Nitroglycerin (Dynamite)FDA LinkGeneric
03/2015 - 10/2006
2EnzymesIBA
06/2018 - 09/2004
2Nitric Oxide Synthase (NO Synthase)IBA
05/2016 - 09/2004
2LipidsIBA
04/2013 - 06/2011
1ClusterinIBA
01/2019
1Docetaxel (Taxotere)FDA Link
01/2019
1ChemokinesIBA
06/2018
1Granzymes (Granzyme)IBA
06/2018
1Peroxynitrous Acid (Peroxynitrite)IBA
05/2016
1InterferonsIBA
05/2016
1Superoxides (Superoxide)IBA
05/2016
1Adenosine Triphosphate (ATP)IBA
03/2015
1Purinergic Receptors (Receptors, Purine)IBA
03/2015
1NitratesIBA
03/2015
1N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA
03/2015
1Oxaliplatin (Eloxatin)FDA LinkGeneric
11/2014
1Cisplatin (Platino)FDA LinkGeneric
11/2014
1PlatinumIBA
11/2014
1LipopolysaccharidesIBA
04/2013
1Death Domain ReceptorsIBA
06/2011
1Biotin (Vitamin H)FDA Link
06/2011
1Fas Ligand Protein (Fas Ligand)IBA
06/2011
1Proteins (Proteins, Gene)FDA Link
09/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2007
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2007
14-(2-aminoethyl)benzenesulfonylfluoride (AEBSF)IBA
10/2006
1Nitric Oxide DonorsIBA
10/2006
1Proteasome Endopeptidase Complex (Proteasome)IBA
10/2006
1beta CateninIBA
10/2006
1LuciferasesIBA
10/2006
1TCF Transcription FactorsIBA
10/2006
1Tosylphenylalanyl Chloromethyl Ketone (TPCK)IBA
10/2006
1Transforming Growth Factor beta (TGF-beta)IBA
01/2005
1Complementary DNA (cDNA)IBA
01/2005
1NF-kappa B (NF-kB)IBA
06/2004
1Transcription Factors (Transcription Factor)IBA
06/2004
1NG-Nitroarginine Methyl Ester (L-NAME)IBA
08/2002
1ArginaseIBA
08/2002

Therapy/Procedure

5Therapeutics
05/2016 - 03/2004
3Drug Therapy (Chemotherapy)
01/2019 - 06/2007
2Immunotherapy
05/2016 - 11/2014
2Injections
11/2014 - 01/2010
1Castration
01/2019
1Intraperitoneal Injections
04/2013
1Aftercare (After-Treatment)
08/2002